Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

As Hain Celestial gears up to become a “pure play” food and beverage supplier, the company sees opportunities linked to GLP-1 ...

Pfizer revealed in December that it had decided to drop the twice-daily version, after seeing rates of discontinuation with the drug above 50% in clinical testing, despite weight loss ranging from ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

This can help individuals feel fuller for longer and can promote weight loss. When measured by traditional weight loss ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

In today’s fast-paced world, many individuals struggle with weight management, feeling overwhelmed by conflicting advice and ...

Millions of Americans use GLP-1 injections like Ozempic to lose weight. A study is questioning whether they can cause vision loss.

Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...